Figure 1 Animal models of liver regeneration

Slides:



Advertisements
Similar presentations
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Advertisements

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 3 Extracellular stimuli to HSC activation
Figure 1 Contribution of the gut microbiota
Figure 4 Activation of clopidogrel via cytochrome P450
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 6 Injection of mesenchymal stem cells in perianal fistulas
Figure 7 Management algorithm for patients with ACLF
Figure 1 Gut microorganisms at the intersection of several diseases
Figure 5 Lipid droplet consumption
Figure 4 Simple perianal fistula
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 2 The microbiome–gut–brain axis
Figure 1 Organs involved in coeliac-disease-associated autoimmunity
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 5 Exosomes for delivery of RNA interference therapeutics
Figure 1 Biosimilar development process
Figure 2 The concept of the hepatic reserve and ACLF
Figure 3 The 'leaky gut' hypothesis
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 2 Effect of PPIs on gastric physiology
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 4 Giant lipid droplet formation
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 6 Combination therapy for HCC
Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection.
Figure 4 Proinflammatory immune cells and their crosstalk in patients with IBD Figure 4 | Proinflammatory immune cells and their crosstalk in patients.
Figure 1 Definition and concept of ACLF
Figure 1 Functions, features and phenotypes of HSCs in normal and diseased livers Figure 1 | Functions, features and phenotypes of HSCs in normal and diseased.
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 2 Switching of biologic agents and biosimilars
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Exosomes with siRNAs targeting
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
to the liver and promote patient-derived xenograft tumour growth
different types of liver cells
Figure 4 Histological pattern in ACLF
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 3 Clinical algorithms in the management of NASH and diabetes mellitus Figure 3 | Clinical algorithms in the management of NASH and diabetes mellitus.
Figure 5 Hepatic regeneration in ACLF
Figure 2 13C-octanoic acid gastric emptying breath test
in the UK (1961–2012), France (1961–2014) and Italy (1961–2010)
Figure 5 Chrononutrition in the liver
Figure 2 Key brain–immune–gut interactions
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 6 Possible therapeutic targets to decrease hepatic steatosis
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 2 Schematic of normal and abnormal liver regeneration
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 3 Strategies to improve liver regeneration
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 5 Systems biological model of IBS
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 NAFLD pathogenesis
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 The spread of colorectal cancer metastases
Presentation transcript:

Figure 1 Animal models of liver regeneration Figure 1 | Animal models of liver regeneration. a | The rat is the classic model for studying liver regeneration following 70% hepatectomy, which results in rapid activation of regenerative signals peaking at 24 h. Hepatocyte proliferation can be inhibited efficiently by toxins. When additional injury such as partial hepatectomy is added, a widespread oval cell response is activated. b | The mouse has similar properties to the rat but with the additional advantage of good transgenic technologies. Hepatocyte proliferation is not readily inhibited using standard methodologies. c | The zebrafish is rapidly gaining favour because it is easy to use, gives rapid results, is cost effective, enables excellent imaging opportunities and permits chemical screening. Forbes, S. J. & Newsome, P. N. (2016) Liver regeneration — mechanisms and models to clinical application Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2016.97